- Secukinumab met primary and key secondary endpoints in two pivotal Phase III studies showing superiority to placebo in patients with adult onset psoriatic arthritis (PsA)
- PsA is a debilitating, long-lasting condition that causes inflammation of joints and skin and affects up to 30% of people with psoriasis globally[1],[2]
- Many people with PsA do not respond to current standard of care, with approximately 45% of people dissatisfied with current treatments[3]
- Secukinumab is the first interleukin-17A (IL-17A) inhibitor with positive Phase III results in PsA and regulatory submissions are planned for 2015
Basel, 25-9-2014 — /EuropaWire/ — Novartis today announced that two pivotal Phase III studies (FUTURE 1 and FUTURE 2) of AIN457 (secukinumab) in psoriatic arthritis (PsA) met primary and key secondary endpoints. Endpoints included improving signs and symptoms of psoriatic arthritis (PsA), including improving peripheral joint disease and preventing joint damage versus placebo, while delivering clear or almost clear skin (PASI 90). Secukinumab is an investigational medicine that works by stopping the action of interleukin-17A (IL-17A)[4], a protein that is central to the development of inflammatory diseases[5]. FUTURE 1 and FUTURE 2 enrolled a combined total of more than 1,000 patients. Detailed results of the studies will be presented at an upcoming medical congress.
PsA is a long-lasting, complex condition involving joint inflammation (arthritis), and usually occurs in combination with psoriasis[1]. There are many different features of PsA that affect the skin, joints and tendons, resulting in irreversible joint damage in many patients[1]. It is linked with significant disability, poor quality of life, reduced life expectancy[1] and major economic burden for the society[6]-[8]. Although TNF (tumor-necrosis-factor) inhibitors, the current standard of care for PsA[10],[11], can improve clinical symptoms[11]-[16], responses may diminish over time. Furthermore, many patients with PsA do not respond to or tolerate these agents[4], leaving an unmet need.
“Building on the positive data previously reported in psoriasis, we are excited to present the first Phase III results of secukinumab in PsA. These positive results are planned to form the basis of a filing application to regulatory authorities in this indication,” said Vasant Narasimhan, Global Head of Development, Novartis Pharmaceuticals. “Effective new therapies are urgently needed for newly PsA diagnosed patients and for nearly half of PsA patients who are dissatisfied with or not responding to their current treatments.”
Global regulatory applications for secukinumab in PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate-to-severe plaque psoriasis which were filed in October 2013 with approvals anticipated in late 2014 or early 2015.
FUTURE 1 and FUTURE 2 are randomized, placebo-controlled, multicenter studies designed to demonstrate efficacy of secukinumab in PsA compared to placebo and to assess safety and tolerability. The American College of Rheumatology response criteria (ACR20) was the primary endpoint in the studies. Secukinumab was well tolerated in both studies. The observed safety profile was consistent with previously reported results from the large psoriasis clinical trial program involving nearly 4,000 patients[17].
About psoriatic arthritis (PsA)
Psoriatic arthritis (PsA) is closely associated with psoriasis; approximately 30% of patients with psoriasis have psoriatic arthritis[2]. It is a debilitating, long-lasting inflammatory disease linked with significant disability, poor quality of life and reduced life expectancy[1]. PsA causes joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis, and irreversible joint damage[1]. Between 0.3% and 1% of the general population may be affected by PsA and as many as one in four people with psoriasis may have undiagnosed PsA[2],[5].
About AIN457 (secukinumab) and interleukin-17A (IL-17A)
AIN457 (secukinumab) is a fully human monoclonal antibody that selectively stops the action of IL-17A[4]. Secukinumab is the first medicine selectively targeting IL-17A with positive Phase III results for the treatment of PsA. IL-17A, a protein that stimulates inflammatory disease, is central to the development of psoriasis and other inflammatory arthritic diseases, including PsA[5].
In addition to PsA, secukinumab is also in clinical trials for the treatment of ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Following the presentation of the first moderate-to-severe plaque psoriasis Phase III results of secukinumab in October 2013, EU and US regulatory filings were submitted at the end of 2013.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as “planned,” “investigational,” “will,” “upcoming,” “may,” “excited,” “anticipated,” or similar terms, or by express or implied discussions regarding potential additional marketing authorizations for secukinumab (AIN457), potential new indications or labeling for AIN457, or regarding potential future revenues from AIN457. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that AIN457 will be approved for sale in any market where it has been submitted, or that it will be submitted or approved for sale in any additional markets, or at any particular time. Neither can there be any guarantee that AIN457 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that AIN457 will be commercially successful in the future. In particular, management’s expectations regarding AIN457 could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; the company’s ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected manufacturing issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visithttp://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
References
[1] Mease PJ, Armstrong AW. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs. 2014; 74:423-441.
[2] Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64:ii14-ii17.
[3] Armstrong A, Robertson A, Wu J, et al. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011.JAMA Dermatol. 2013; 149(10):1180-1185.
[4] Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014; 141:133-42.
[5] Van Baarsen LGM, Lebre MC, van der Coelen D, et al. IL-17 levels in synovium of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis: Target validation in various forms of arthritis. Ann Rheum Dis. 2011;70:A79.
[6] Lee S, Mendelsohn and A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680 689.
[7] Poole CD et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology Advance Access. Doi: 10.1093/rheumatology/keq182
[8] Huscher D1 et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 Sep;65(9):1175-83. Epub 2006 Mar 15.
[9] Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2011; 65:137-74.
[10] Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept Treatment of Psoriatic Arthritis.Arthritis Rheum. 2004; 50:2264-72.
[11] Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the Treatment of Patients With Moderately to Severely Active Psoriatic Arthritis. Arthritis Rheum. 2005; 52:3279-89.
[12] Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005; 64:1150-7.
[13] Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a New Human Tumor Necrosis Factor Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis. Arthritis Rheum. 2009; 60:976-86.
[14] Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014; 73:48-55.
[15] Carl Orr, Douglas James Veale. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis? Ann Rheum Dis June 2014 Vol 73 No 6.
[16] National Psoriasis Foundation (NPF) website. “2011 Survey Panel Snapshot for Psoriatic Arthritis.” http://www.psoriasis.org/document.doc?id=1782. Accessed December 2013.
[17] Novartis data on file. 2013: Clinical study reports for CAIN457A2302 [ERASURE] ; CAIN457A2303 [FIXTURE] ; CAIN457A2304 [SCULPTURE] ; CAIN457A2307 [JUNCTURE] ; CAIN457A2308 [FEATURE].
# # #
Novartis Media Relations
Central media line: +41 61 324 2200 | |
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Katrina Lucking Novartis Global Pharma Communications +41 61 324 1218 (direct) +41 79 171 8267 (mobile) katrina.lucking@novartis.com |
e-mail: media.relations@novartis.com
For Novartis multimedia content, please visit: www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:journalisthelp@thenewsmarket.com.
Novartis Investor Relations
Central phone: | +41 61 324 7944 | North America: | |
Samir Shah | +41 61 324 7944 | Stephen Rubino | +1 862 778 8301 |
Pierre-Michel Bringer | +41 61 324 1065 | Susan Donofrio | +1 862 778 9257 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 | ||
e-mail: investor.relations@novartis.com | e-mail: investor.relations@novartis.com |
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
- BREAKING NEWS: New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives Through Hope and Community in Recovery
- Cha Cha Cha kohtub krüptomaailmaga: Winz.io teeb koostööd Euroopa visionääri ja staari Käärijäga
- Digi Communications N.V. announces Conditional stock options granted to Executive Directors of the Company, for the year 2025, based on the general shareholders’ meeting approval from 25 June 20244
- Cha Cha Cha meets crypto: Winz.io partners with European visionary star Käärijä
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2024, as approved by the Company’s OGSM from 25 June 2024
- “Su Fortuna Se Ha Construido A Base de La Defraudación Fiscal”: Críticas Resurgen Contra Ricardo Salinas en Medio de Nuevas Revelaciones Judiciales y Fiscaleso
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2024 financial year
- SOILRES project launches to revive Europe’s soils and future-proof farming
- Josh Case, ancien cadre d’ENGIE Amérique du Nord, PDG de Photosol US Renewable Energy et consultant d’EDF Amérique du Nord, engage aujourd’hui toute son énergie dans la lutte contre la dépendance
- Bizzy startet den AI Sales Agent in Deutschland: ein intelligenter Agent zur Automatisierung der Vertriebspipeline
- Bizzy lance son agent commercial en France : un assistant intelligent qui automatise la prospection
- Bizzy lancia l’AI Sales Agent in Italia: un agente intelligente che automatizza la pipeline di vendita
- Bizzy lanceert AI Sales Agent in Nederland: slimme assistent automatiseert de sales pipeline
- Bizzy startet AI Sales Agent in Österreich: ein smarter Agent, der die Sales-Pipeline automatisiert
- Bizzy wprowadza AI Sales Agent w Polsce: inteligentny agent, który automatyzuje budowę lejka sprzedaży
- Bizzy lanza su AI Sales Agent en España: un agente inteligente que automatiza la generación del pipeline de ventas
- Bizzy launches AI Sales Agent in the UK: a smart assistant that automates sales pipeline generation
- As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2024 Annual Report
- Escándalo Judicial en Aumento Alarma a la Opinión Pública: Suprema Corte de México Enfrenta Acusaciones de Favoritismo hacia el Aspirante a Magnate Ricardo Salinas Pliego
- Winz.io Named AskGamblers’ Best Casino 2025
- Kissflow Doubles Down on Germany as a Strategic Growth Market with New AI Features and Enterprise Focus
- Digi Communications N.V. announces Share transaction made by a Non-Executive Director of the Company with class B shares
- Salinas Pliego Intenta Frenar Investigaciones Financieras: UIF y Expertos en Corrupción Prenden Alarmas
- Digital integrity at risk: EU Initiative to strengthen the Right to be forgotten gains momentum
- Orden Propuesta De Arresto E Incautación Contra Ricardo Salinas En Corte De EE.UU
- Digi Communications N.V. announced that Serghei Bulgac, CEO and Executive Director, sold 15,000 class B shares of the company’s stock
- PFMcrypto lancia un sistema di ottimizzazione del reddito basato sull’intelligenza artificiale: il mining di Bitcoin non è mai stato così facile
- Azteca Comunicaciones en Quiebra en Colombia: ¿Un Presagio para Banco Azteca?
- OptiSigns anuncia su expansión Europea
- OptiSigns annonce son expansion européenne
- OptiSigns kündigt europäische Expansion an
- OptiSigns Announces European Expansion
- Digi Communications NV announces release of Q1 2025 financial report
- Banco Azteca y Ricardo Salinas Pliego: Nuevas Revelaciones Aumentan la Preocupación por Riesgos Legales y Financieros
- Digi Communications NV announces Investors Call for the presentation of the Q1 2025 Financial Results
- Digi Communications N.V. announces the publication of the 2024 Annual Financial Report and convocation of the Company’s general shareholders meeting for June 18, 2025, for the approval of, among others, the 2024 Annual Financial Report, available on the Company’s website
- La Suprema Corte Sanciona a Ricardo Salinas de Grupo Elektra por Obstrucción Legal
- Digi Communications N.V. announces the conclusion of an Incremental to the Senior Facilities Agreement dated 21 April 2023
- 5P Europe Foundation: New Initiative for African Children
- 28-Mar-2025: Digi Communications N.V. announces the conclusion of Facilities Agreements by companies within Digi Group
- Aeroluxe Expeditions Enters U.S. Market with High-Touch Private Jet Journeys—At a More Accessible Price ↗️
- SABIO GROUP TAKES IT’S ‘DISRUPT’ CX PROGRAMME ACROSS EUROPE
- EU must invest in high-quality journalism and fact-checking tools to stop disinformation
- ¿Está Banco Azteca al borde de la quiebra o de una intervención gubernamental? Preocupaciones crecientes sobre la inestabilidad financiera
- Netmore and Zenze Partner to Deploy LoRaWAN® Networks for Cargo and Asset Monitoring at Ports and Terminals Worldwide
- Rise Point Capital: Co-investing with Independent Sponsors to Unlock International Investment Opportunities
- Netmore Launches Metering-as-a-Service to Accelerate Smart Metering for Water and Gas Utilities
- Digi Communications N.V. announces that a share transaction was made by a Non-Executive Director of the Company with class B shares
- La Ballata del Trasimeno: Il Mediometraggio si Trasforma in Mini Serie
- Digi Communications NV Announces Availability of 2024 Preliminary Financial Report
- Digi Communications N.V. announces the recent evolution and performance of the Company’s subsidiary in Spain
- BevZero Equipment Sales and Distribution Enhances Dealcoholization Capabilities with New ClearAlc 300 l/h Demonstration Unit in Spain Facility
- Digi Communications NV announces Investors Call for the presentation of the 2024 Preliminary Financial Results
- Reuters webinar: Omnibus regulation Reuters post-analysis
- Patients as Partners® Europe Launches the 9th Annual Event with 2025 Keynotes, Featured Speakers and Topics
- eVTOLUTION: Pioneering the Future of Urban Air Mobility
- Reuters webinar: Effective Sustainability Data Governance
- Las acusaciones de fraude contra Ricardo Salinas no son nuevas: una perspectiva histórica sobre los problemas legales del multimillonario
- Digi Communications N.V. Announces the release of the Financial Calendar for 2025
- USA Court Lambasts Ricardo Salinas Pliego For Contempt Of Court Order
- 3D Electronics: A New Frontier of Product Differentiation, Thinks IDTechEx
- Ringier Axel Springer Polska Faces Lawsuit for Over PLN 54 million
- Digi Communications N.V. announces the availability of the report on corporate income tax information for the financial year ending December 31, 2023
- Unlocking the Multi-Million-Dollar Opportunities in Quantum Computing
- Digi Communications N.V. Announces the Conclusion of Facilities Agreements by Companies within Digi Group
- The Hidden Gem of Deep Plane Facelifts
- KAZANU: Redefining Naturist Hospitality in Saint Martin ↗️
- New IDTechEx Report Predicts Regulatory Shifts Will Transform the Electric Light Commercial Vehicle Market
- Almost 1 in 4 Planes Sold in 2045 to be Battery Electric, Finds IDTechEx Sustainable Aviation Market Report
- Digi Communications N.V. announces the release of Q3 2024 financial results
- Digi Communications NV announces Investors Call for the presentation of the Q3 2024 Financial Results
- Pilot and Electriq Global announce collaboration to explore deployment of proprietary hydrogen transport, storage and power generation technology
- Digi Communications N.V. announces the conclusion of a Memorandum of Understanding by its subsidiary in Romania
- Digi Communications N.V. announces that the Company’s Portuguese subsidiary finalised the transaction with LORCA JVCO Limited
- Digi Communications N.V. announces that the Portuguese Competition Authority has granted clearance for the share purchase agreement concluded by the Company’s subsidiary in Portugal
- OMRON Healthcare introduceert nieuwe bloeddrukmeters met AI-aangedreven AFib-detectietechnologie; lancering in Europa september 2024
- OMRON Healthcare dévoile de nouveaux tensiomètres dotés d’une technologie de détection de la fibrillation auriculaire alimentée par l’IA, lancés en Europe en septembre 2024
- OMRON Healthcare presenta i nuovi misuratori della pressione sanguigna con tecnologia di rilevamento della fibrillazione atriale (AFib) basata sull’IA, in arrivo in Europa a settembre 2024
- OMRON Healthcare presenta los nuevos tensiómetros con tecnología de detección de fibrilación auricular (FA) e inteligencia artificial (IA), que se lanzarán en Europa en septiembre de 2024
- Alegerile din Moldova din 2024: O Bătălie pentru Democrație Împotriva Dezinformării
- Northcrest Developments launches design competition to reimagine 2-km former airport Runway into a vibrant pedestrianized corridor, shaping a new era of placemaking on an international scale
- The Road to Sustainable Electric Motors for EVs: IDTechEx Analyzes Key Factors
- Infrared Technology Breakthroughs Paving the Way for a US$500 Million Market, Says IDTechEx Report
- MegaFair Revolutionizes the iGaming Industry with Skill-Based Games
- European Commission Evaluates Poland’s Media Adherence to the Right to be Forgotten
- Global Race for Autonomous Trucks: Europe a Critical Region Transport Transformation
- Digi Communications N.V. confirms the full redemption of €450,000,000 Senior Secured Notes
- AT&T Obtiene Sentencia Contra Grupo Salinas Telecom, Propiedad de Ricardo Salinas, Sus Abogados se Retiran Mientras Él Mueve Activos Fuera de EE.UU. para Evitar Pagar la Sentencia
- Global Outlook for the Challenging Autonomous Bus and Roboshuttle Markets
- Evolving Brain-Computer Interface Market More Than Just Elon Musk’s Neuralink, Reports IDTechEx
- Latin Trails Wraps Up a Successful 3rd Quarter with Prestigious LATA Sustainability Award and Expands Conservation Initiatives ↗️
- Astor Asset Management 3 Ltd leitet Untersuchung für potenzielle Sammelklage gegen Ricardo Benjamín Salinas Pliego von Grupo ELEKTRA wegen Marktmanipulation und Wertpapierbetrug ein
- Digi Communications N.V. announces that the Company’s Romanian subsidiary exercised its right to redeem the Senior Secured Notes due in 2025 in principal amount of €450,000,000
- Astor Asset Management 3 Ltd Inicia Investigación de Demanda Colectiva Contra Ricardo Benjamín Salinas Pliego de Grupo ELEKTRA por Manipulación de Acciones y Fraude en Valores
- Astor Asset Management 3 Ltd Initiating Class Action Lawsuit Inquiry Against Ricardo Benjamín Salinas Pliego of Grupo ELEKTRA for Stock Manipulation & Securities Fraud
- Digi Communications N.V. announced that its Spanish subsidiary, Digi Spain Telecom S.L.U., has completed the first stage of selling a Fibre-to-the-Home (FTTH) network in 12 Spanish provinces
- Natural Cotton Color lancia la collezione "Calunga" a Milano
- Astor Asset Management 3 Ltd: Salinas Pliego Incumple Préstamo de $110 Millones USD y Viola Regulaciones Mexicanas
- Astor Asset Management 3 Ltd: Salinas Pliego Verstößt gegen Darlehensvertrag über 110 Mio. USD und Mexikanische Wertpapiergesetze
- ChargeEuropa zamyka rundę finansowania, której przewodził fundusz Shift4Good tym samym dokonując historycznej francuskiej inwestycji w polski sektor elektromobilności
- Strengthening EU Protections: Robert Szustkowski calls for safeguarding EU citizens’ rights to dignity
- Digi Communications NV announces the release of H1 2024 Financial Results
- Digi Communications N.V. announces that conditional stock options were granted to a director of the Company’s Romanian Subsidiary
- Digi Communications N.V. announces Investors Call for the presentation of the H1 2024 Financial Results
- Digi Communications N.V. announces the conclusion of a share purchase agreement by its subsidiary in Portugal
- Digi Communications N.V. Announces Rating Assigned by Fitch Ratings to Digi Communications N.V.
- Digi Communications N.V. announces significant agreements concluded by the Company’s subsidiaries in Spain
- SGW Global Appoints Telcomdis as the Official European Distributor for Motorola Nursery and Motorola Sound Products
- Digi Communications N.V. announces the availability of the instruction regarding the payment of share dividend for the 2023 financial year
- Digi Communications N.V. announces the exercise of conditional share options by the executive directors of the Company, for the year 2023, as approved by the Company’s Ordinary General Shareholders’ Meetings from 18th May 2021 and 28th December 2022
- Digi Communications N.V. announces the granting of conditional stock options to Executive Directors of the Company based on the general shareholders’ meeting approval from 25 June 2024
- Digi Communications N.V. announces the OGMS resolutions and the availability of the approved 2023 Annual Report
- Czech Composer Tatiana Mikova Presents Her String Quartet ‘In Modo Lidico’ at Carnegie Hall
- SWIFTT: A Copernicus-based forest management tool to map, mitigate, and prevent the main threats to EU forests
- WickedBet Unveils Exciting Euro 2024 Promotion with Boosted Odds
- Museum of Unrest: a new space for activism, art and design
- Digi Communications N.V. announces the conclusion of a Senior Facility Agreement by companies within Digi Group
- Digi Communications N.V. announces the agreements concluded by Digi Romania (formerly named RCS & RDS S.A.), the Romanian subsidiary of the Company
- Green Light for Henri Hotel, Restaurants and Shops in the “Alter Fischereihafen” (Old Fishing Port) in Cuxhaven, opening Summer 2026
- Digi Communications N.V. reports consolidated revenues and other income of EUR 447 million, adjusted EBITDA (excluding IFRS 16) of EUR 140 million for Q1 2024
- Digi Communications announces the conclusion of Facilities Agreements by companies from Digi Group
- Digi Communications N.V. Announces the convocation of the Company’s general shareholders meeting for 25 June 2024 for the approval of, among others, the 2023 Annual Report
- Digi Communications NV announces Investors Call for the presentation of the Q1 2024 Financial Results
- Digi Communications intends to propose to shareholders the distribution of dividends for the fiscal year 2023 at the upcoming General Meeting of Shareholders, which shall take place in June 2024
- Digi Communications N.V. announces the availability of the Romanian version of the 2023 Annual Report
- Digi Communications N.V. announces the availability of the 2023 Annual Report
- International Airlines Group adopts Airline Economics by Skailark ↗️
- BevZero Spain Enhances Sustainability Efforts with Installation of Solar Panels at Production Facility
- Digi Communications N.V. announces share transaction made by an Executive Director of the Company with class B shares
- BevZero South Africa Achieves FSSC 22000 Food Safety Certification
- Digi Communications N.V.: Digi Spain Enters Agreement to Sell FTTH Network to International Investors for Up to EUR 750 Million
- Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics
- driveMybox continues its international expansion: Hungary as a new strategic location
- Monesave introduces Socialised budgeting: Meet the app quietly revolutionising how users budget
- Digi Communications NV announces the release of the 2023 Preliminary Financial Results
- Digi Communications NV announces Investors Call for the presentation of the 2023 Preliminary Financial Results
- Lensa, един от най-ценените търговци на оптика в Румъния, пристига в България. Първият шоурум е открит в София
- Criando o futuro: desenvolvimento da AENO no mercado de consumo em Portugal
- Digi Communications N.V. Announces the release of the Financial Calendar for 2024
- Customer Data Platform Industry Attracts New Participants: CDP Institute Report
- eCarsTrade annonce Dirk Van Roost au poste de Directeur Administratif et Financier: une décision stratégique pour la croissance à venir
- BevZero Announces Strategic Partnership with TOMSA Desil to Distribute equipment for sustainability in the wine industry, as well as the development of Next-Gen Dealcoholization technology
- Editor's pick archive....